All In Biotech

Drug Trial Radar · NCT07886554

LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)

A Double Blind, Placebo-controlled Trial of LAM-001 for Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2028

Study completion Jun 2029

Sponsor

Lead sponsor
IRulya Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Oct 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 (Inhaled Sirolimus) in Adults with Sarcoidosis Associated Pulmonary Hypertension (SAPH)

Conditions

  • Sarcoidosis Associated Pulmonary Hypertension

Interventions

  • PlaceboDrug

    Matching placebo administered via dry powder inhalation

  • LAM-001Drug

    LAM-001 administered via dry powder inhaler

  • LAM-001Drug

    LAM-001 administered via dry powder inhaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Pulmonary Vascular Resistance (PVR) at 24 weeksTime frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Temple University

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.